Belgium's UCB 2025 revenue up 26%, beats expectations on strong execution of key products

UCB SA

26/02/2026 06:12

Overview

Belgium-based biopharma's 2025 revenue rose 26%, beating analyst expectations

Adjusted EBITDA for 2025 increased 79%, driven by strategic investments

Company's clinical pipeline advances with eight innovative treatment options under study

Outlook

UCB expects 2026 revenue growth in high single-digit to low double-digit range at CER

Company forecasts 2026 adjusted EBITDA growth in high single-digit to high teens range at CER

Corrected 2026 adjusted EBITDA growth expected in high teens to high twenties range at CER

Result Drivers

GROWTH DRIVERS - UCB's revenue growth was driven by strong execution of its key products, BIMZELX, EVENITY, FINTEPLA, RYSTIGGO, and ZILBRYSQ, which more than doubled their combined net sales

PRODUCT MIX - Improved product mix contributed to higher gross profit, reflecting the success of UCB's growth drivers

REGULATORY APPROVALS - New regulatory approvals, including KYGEVVI in the U.S. and EU, expanded UCB's neuromuscular footprint

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
EUR 7.74 bln
EUR 7.54 bln (22 Analysts)
FY Adjusted EPS
EUR 9.99


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)